Current preclinical models for the advancement of translational bladder cancer research

David J. DeGraff, Victoria L. Robinson, Jay B. Shah, William D. Brandt, Guru Sonpavde, Yibin Kang, Monica Liebert, Xue Ru Wu, John A. Taylor

Research output: Contribution to journalReview article

14 Citations (Scopus)

Abstract

Bladder cancer is a common disease representing the fifth most diagnosed solid tumor in the United States. Despite this, advances in our understanding of the molecular etiology and treatment of bladder cancer have been relatively lacking. This is especially apparent when recent advances in other cancers, such as breast and prostate, are taken into consideration. The field of bladder cancer research is ready and poised for a series of paradigm-shifting discoveries that will greatly impact the way this disease is clinically managed. Future preclinical discoveries with translational potential will require investigators to take full advantage of recent advances in molecular and animal modeling methodologies. We present an overview of current preclinical models and their potential roles in advancing our understanding of this deadly disease and for advancing care.

Original languageEnglish (US)
Pages (from-to)121-130
Number of pages10
JournalMolecular cancer therapeutics
Volume12
Issue number2
DOIs
StatePublished - Feb 1 2013

Fingerprint

Urinary Bladder Neoplasms
Erythema Infectiosum
Research
Prostate
Neoplasms
Breast
Research Personnel

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

DeGraff, D. J., Robinson, V. L., Shah, J. B., Brandt, W. D., Sonpavde, G., Kang, Y., ... Taylor, J. A. (2013). Current preclinical models for the advancement of translational bladder cancer research. Molecular cancer therapeutics, 12(2), 121-130. https://doi.org/10.1158/1535-7163.MCT-12-0508
DeGraff, David J. ; Robinson, Victoria L. ; Shah, Jay B. ; Brandt, William D. ; Sonpavde, Guru ; Kang, Yibin ; Liebert, Monica ; Wu, Xue Ru ; Taylor, John A. / Current preclinical models for the advancement of translational bladder cancer research. In: Molecular cancer therapeutics. 2013 ; Vol. 12, No. 2. pp. 121-130.
@article{20f2783c362148ffb195e02d9ae7a3f0,
title = "Current preclinical models for the advancement of translational bladder cancer research",
abstract = "Bladder cancer is a common disease representing the fifth most diagnosed solid tumor in the United States. Despite this, advances in our understanding of the molecular etiology and treatment of bladder cancer have been relatively lacking. This is especially apparent when recent advances in other cancers, such as breast and prostate, are taken into consideration. The field of bladder cancer research is ready and poised for a series of paradigm-shifting discoveries that will greatly impact the way this disease is clinically managed. Future preclinical discoveries with translational potential will require investigators to take full advantage of recent advances in molecular and animal modeling methodologies. We present an overview of current preclinical models and their potential roles in advancing our understanding of this deadly disease and for advancing care.",
author = "DeGraff, {David J.} and Robinson, {Victoria L.} and Shah, {Jay B.} and Brandt, {William D.} and Guru Sonpavde and Yibin Kang and Monica Liebert and Wu, {Xue Ru} and Taylor, {John A.}",
year = "2013",
month = "2",
day = "1",
doi = "10.1158/1535-7163.MCT-12-0508",
language = "English (US)",
volume = "12",
pages = "121--130",
journal = "Molecular Cancer Therapeutics",
issn = "1535-7163",
publisher = "American Association for Cancer Research Inc.",
number = "2",

}

DeGraff, DJ, Robinson, VL, Shah, JB, Brandt, WD, Sonpavde, G, Kang, Y, Liebert, M, Wu, XR & Taylor, JA 2013, 'Current preclinical models for the advancement of translational bladder cancer research', Molecular cancer therapeutics, vol. 12, no. 2, pp. 121-130. https://doi.org/10.1158/1535-7163.MCT-12-0508

Current preclinical models for the advancement of translational bladder cancer research. / DeGraff, David J.; Robinson, Victoria L.; Shah, Jay B.; Brandt, William D.; Sonpavde, Guru; Kang, Yibin; Liebert, Monica; Wu, Xue Ru; Taylor, John A.

In: Molecular cancer therapeutics, Vol. 12, No. 2, 01.02.2013, p. 121-130.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Current preclinical models for the advancement of translational bladder cancer research

AU - DeGraff, David J.

AU - Robinson, Victoria L.

AU - Shah, Jay B.

AU - Brandt, William D.

AU - Sonpavde, Guru

AU - Kang, Yibin

AU - Liebert, Monica

AU - Wu, Xue Ru

AU - Taylor, John A.

PY - 2013/2/1

Y1 - 2013/2/1

N2 - Bladder cancer is a common disease representing the fifth most diagnosed solid tumor in the United States. Despite this, advances in our understanding of the molecular etiology and treatment of bladder cancer have been relatively lacking. This is especially apparent when recent advances in other cancers, such as breast and prostate, are taken into consideration. The field of bladder cancer research is ready and poised for a series of paradigm-shifting discoveries that will greatly impact the way this disease is clinically managed. Future preclinical discoveries with translational potential will require investigators to take full advantage of recent advances in molecular and animal modeling methodologies. We present an overview of current preclinical models and their potential roles in advancing our understanding of this deadly disease and for advancing care.

AB - Bladder cancer is a common disease representing the fifth most diagnosed solid tumor in the United States. Despite this, advances in our understanding of the molecular etiology and treatment of bladder cancer have been relatively lacking. This is especially apparent when recent advances in other cancers, such as breast and prostate, are taken into consideration. The field of bladder cancer research is ready and poised for a series of paradigm-shifting discoveries that will greatly impact the way this disease is clinically managed. Future preclinical discoveries with translational potential will require investigators to take full advantage of recent advances in molecular and animal modeling methodologies. We present an overview of current preclinical models and their potential roles in advancing our understanding of this deadly disease and for advancing care.

UR - http://www.scopus.com/inward/record.url?scp=84874032693&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84874032693&partnerID=8YFLogxK

U2 - 10.1158/1535-7163.MCT-12-0508

DO - 10.1158/1535-7163.MCT-12-0508

M3 - Review article

C2 - 23269072

AN - SCOPUS:84874032693

VL - 12

SP - 121

EP - 130

JO - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

SN - 1535-7163

IS - 2

ER -